Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Preoperative Gemcitabine and Bevacizumab in Resectable Pancreatic Cancer
NCT00336648Phase 2Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Jun 2006
- Primary completion
- Sep 2007
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of bevacizumab in pancreatic adenocarcinoma (PDAC), sponsored by University of Texas MD Anderson Cancer Center. Started Jun 2006; status: completed.
02
Drugs
bevacizumab
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT00336648.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00336648.